Andrew M. Dahl
Known title: SVP, Corporate ControllerCIK: 0002022347
Associated companies
Transaction History
| EW | ▼ Sell | Tax Withholding | 253 | $21K | 9/13/2026 | View on chart |
| EW | ▼ Sell | Open Market | 544 | $50K | 8/31/2026 | View on chart |
| EW | ▼ Sell | Open Market | 568 | $49K | 5/29/2026 | View on chart |
| EW | ▼ Sell | Tax Withholding | 289 | $24K | 5/8/2026 | View on chart |
| EW | ▲ Buy | Grant | 3,985 | $0 | 5/7/2026 | View on chart |
| EW | ▲ Buy | Grant | 3,020 | $0 | 5/7/2026 | View on chart |
| EW | ▼ Sell | Tax Withholding | 176 | $14K | 2/22/2026 | View on chart |
| EW | ▲ Buy | Grant | 1,160 | $0 | 11/13/2025 | View on chart |
| EW | ▼ Sell | Tax Withholding | 262 | $20K | 9/13/2025 | View on chart |
| EW | ▲ Buy | Grant | 3,335 | $0 | 5/8/2025 | View on chart |
| EW | ▼ Sell | Tax Withholding | 176 | $13K | 2/22/2025 | View on chart |
| EW | ▲ Buy | Grant | 2,920 | $0 | 9/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death
The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.